MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Thu Oct 25 00:00:00 GMT-05:00 2018
Daiichi Sankyo Announces Clinical Research Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate [Fam-] Trastuzumab Deruxtecan (DS-8201) with Avelumab and a DNA Damage Response Inhibitor in Patients with HER2 Expressing and Mutated Solid Tumors
Download
Tue Oct 23 00:00:00 GMT-05:00 2018
Daiichi Sankyo, Inc. Publishes Second Edition of Pain Trends Report
Download
Sun Oct 21 00:00:00 GMT-05:00 2018
Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress
Download
Thu Oct 18 00:00:00 GMT-05:00 2018
Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
Download
Wed Oct 17 00:00:00 GMT-05:00 2018
Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Download
Wed Oct 03 00:00:00 GMT-05:00 2018
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma
Download
Tue Sep 25 00:00:00 GMT-05:00 2018
Daiichi Sankyo Initiates Two Phase 3 Trials of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Positive Metastatic Breast Cancer including Head-to-Head Versus T-DM1 and Post-T-DM1 Study
Download
Mon Sep 24 00:00:00 GMT-05:00 2018
Daiichi Sankyo Presents Updated Results for [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Mutated or HER2 Expressing Non-Small Cell Lung Cancer at IASLC 19th World Conference on Lung Cancer
Download
Thu Sep 20 00:00:00 GMT-05:00 2018
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers
Download
Tue Sep 11 00:00:00 GMT-05:00 2018
Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Receives Orphan Drug Designation from Japanese MHLW for FLT3-Mutated AML
Download